Traders bought shares of Johnson & Johnson (NYSE:JNJ) on weakness during trading on Monday. $202.92 million flowed into the stock on the tick-up and $133.32 million flowed out of the stock on the tick-down, for a money net flow of $69.60 million into the stock. Of all equities tracked, Johnson & Johnson had the 18th highest net in-flow for the day. Johnson & Johnson traded down ($0.97) for the day and closed at $139.01
Several analysts recently weighed in on JNJ shares. Credit Suisse Group set a $154.00 price target on Johnson & Johnson and gave the stock an “outperform” rating in a research note on Thursday, October 19th. Royal Bank Of Canada upped their price target on Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 18th. Citigroup started coverage on Johnson & Johnson in a research note on Monday, September 25th. They issued a “neutral” rating and a $140.00 price target on the stock. Goldman Sachs Group cut Johnson & Johnson from a “neutral” rating to a “sell” rating and upped their price objective for the company from $125.00 to $130.00 in a research report on Wednesday, September 20th. Finally, Jefferies Group raised Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price objective for the company from $145.00 to $157.00 in a research report on Wednesday, October 11th. Four analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $144.59.
The firm has a market cap of $373,450.00, a PE ratio of 19.60, a PEG ratio of 2.85 and a beta of 0.80. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company’s revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.68 EPS. equities research analysts expect that Johnson & Johnson will post 7.28 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be issued a dividend of $0.84 per share. The ex-dividend date is Monday, November 27th. This represents a $3.36 annualized dividend and a dividend yield of 2.42%. Johnson & Johnson’s payout ratio is 58.33%.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in JNJ. Harding Loevner LP purchased a new stake in shares of Johnson & Johnson in the 2nd quarter worth $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in shares of Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. increased its stake in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares in the last quarter. IHT Wealth Management LLC increased its stake in shares of Johnson & Johnson by 46.4% in the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after purchasing an additional 3,467 shares in the last quarter. Finally, Mountain Capital Investment Advisors Inc purchased a new stake in shares of Johnson & Johnson in the 2nd quarter worth $124,000. 65.90% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “Traders Buy Johnson & Johnson (JNJ) on Weakness” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/04/traders-buy-johnson-johnson-jnj-on-weakness.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.